אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 10 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; pyridoxine hydrochloride, quantity: 5 mg/ml; dexpanthenol, quantity: 2.5 mg/ml; nicotinamide, quantity: 25 mg/ml; cyanocobalamin, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. commonly, several b vitamin deficiencies may occur similtaneously. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 5. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2, b6 and b12. 6. peripheral neuritis caused by various b group deficiencies. 7.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

unit dose services - nortriptyline hydrochloride (unii: 00fn6ih15d) (nortriptyline - unii:bl03sy4lxb) - nortriptyline 25 mg - nortriptyline hydrochloride is indicated for the relief of symptoms of depression. endogenous depressions are more likely to be alleviated than are other depressive states. the use of maois intended to treat psychiatric disorders with nortriptyline hydrochloride or within 14 days of stopping treatment with nortriptyline hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of nortriptyline hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see warnings and dosage and administration ). starting nortriptyline hydrochloride in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings and dosage and administration ). cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility. nortriptyline hydrochloride is contraindicated during the acute recovery period

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. pernicious anaemia as a result of in situ b12 deficiency.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - cobalamin deficiency may exist that is unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of vitamin b12 may be insufficient in pernicious anaemia, malabsorption disorders, gastrectomy and gastrointestinal pathologies. specific indications may include: 1. pernicious anaemia as a result of in situ b12 deficiency.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 100 mg/ml; disodium edetate, quantity: 60 mg/ml - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - 1. disodium edetate is particularly effective in treating lead accumulation and lead poisoning. this is especially so where there is a concomitant hypercalcaemic problem (refer "indications (2)"). however it must be noted that disodium edetate is equally effective with calcium disodium edetate in removing heavy metals, even in the absence of hypercalcaemia. for patients with elevated serum calcium or hypermobility of their body pools of calcium where there may be transiently or prolonged raised serum calcium (see "indications (2)"), the edta of choice for removing heavy metals may be disodium edetate. there are no recognised safe limits for lead intoxication. lead poisoning may occur by ingestion or inhalation of lead dust or fumes. poisoning is manifested by a metallic taste, anorexia, irritability, apathy, abdominal colic, vomiting, diarrhoea, constipation, headache, leg cramps, black stools, oliguria, stupor, convulsions, palsies and coma. chronic lead poisoning causes variable involvement of the central n

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 90 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate injections are indicated for the treatment of vitamin c deficiency when oral treatment is not feasible

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 150 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.